Name: Aditya Hongunti

NUID: 001529265
Course Name: The Biotechnology Enterprise
Course Name & Number: BIOT5219
Section Number: SEC 06 Fall 2022
Module Number/Assignment number: Module 3/ Assignment 3
Date: October 25th, 2022

1) What leadership style or personality traits do you think best drives strategy and market
intel (knowing your physicians, patients, and competitors) focus?
Answer:
There is no one size fits all when it comes to a leadership style according to me. However, there
is one leadership style that can be developed while keeping it flexible enough to adapt to the
changing needs. The leadership style according to me to drive strategy and market intel should
encompass the following traits (5 Biopharma Execs Reveal Corporate Culture Best Practices,
n.d.):
 Strategic vision: Without the ability to have a strategic vision, the leaders will not be able
to clearly define the approach that has to be taken while delivering the project or defining
the strategy of the project or market intel
 Flexibility in approach: With changing needs and unpresented challenges that can come
up in a project, the leadership style should be able to adapt and be flexible to change or
update the approach to the project.
 Team Management: Within the biotech industry, various stakeholders play a vital role in
developing the drug and taking it to the market, so a leadership style that will be able to
clearly communicate and manage a diverse set of individuals with their specific skillset
and knowledge towards a common goal is a necessary personality trait
 Discipline and time management: The biotech product process is usually quite long and
takes a considerable amount of time from its inception to market and hence ensuring that
the process is timed in an efficient manner while keeping the stakeholder engagement is
highly necessary.
References
5 Biopharma Execs Reveal Corporate Culture Best Practices. (n.d.). Retrieved October 25,
2022, from https://www.lifescienceleader.com/doc/biopharma-execs-reveal-corporate-culture-
best-practices-0001
 2) What surprised you about what you learned regarding general pitch deck content and the
diverse funding options?
Answer:
The pitch deck is a vital aspect and one of the crucial tools in the initial process of sourcing
funding for the biotech product. The pitch deck is used by biotech companies to provide
information about the product and the benefits or diseases the product is supposed to address to
the investors. One of the most surprising aspects of the pitch deck for me was the fact that the
pitch decks work in a way that filter out the type of investors or investing the biotech firm is
looking for as the pitch deck defines the kind of product and the process of development the
product is at. The content in the pitch decks is aligned OR structured in such a way that it varies
in the knowledge the investor may possess regarding their expertise in the healthcare industry
(Shimasaki, 2016). Apart surprising aspect was the fact that there are now numerous funding
options available for the biotech firms involving:
 Bootstrapping the venture which allows greater control and possibly increases the
motivation of the bootstrappers in this case the scientist or parties that are developing the
drug to ensure that their money is used in the best possible manner
 Finance through bank
 Finance through investors who are willing to accept revenue shares
 Angel investing
 Venture Capital
References
Kenton, W. (2020, November 7). What Is Bootstrapping? Investopedia.
https://www.investopedia.com/terms/b/bootstrapping.asp
Shimasaki, C. (2016, December 15). How to Develop a PowerPoint Pitch Deck for Biotech
Investor Presentations. BioSource Consulting Group. https://biosourceconsulting.com/develop-
powerpoint-pitch-deck-biotech-investor-presentations/
3) Who-- which role in the organization-- is accountable for funding?
Answer:
From the information provided in the 5 in 10’s by Prof. Dhimo, it is evident that the Chief
Executive officer or the chief scientist or the funding department is accountable for funding. As
these individuals know most about the product and the patient, they are better able to manage the
funding provided by the investors and can better account for the same Dhimo, C. (2022).
References
Dhimo, C. (2022). BIOT 5219 Module 3's 5 in 10 [video file].
https://northeastern.instructure.com/courses/102442/files/13202286?module_item_id=6828012
4) Who in the organization should be involved with the investors?
Answer:
The individual or team that should be involved with the investors should be the ones that know
about the product and the patients the product is supposed to provide a solution for. As these
individuals know the overall nuances of the business in terms of the inception of the product to
its product deployment in the market, these should be involved in interactions with the investors.
These usually happen to be the CEO or the chief scientist of the firm as they are well versed with
the journey of the product Dhimo, C. (2022).
References
Dhimo, C. (2022). BIOT 5219 Module 3's 5 in 10 [video file].
https://northeastern.instructure.com/courses/102442/files/13202286?module_item_id=6828012